Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
News|Podcasts|November 16, 2026 (Updated: November 16, 2026)

The BioPharm Brief: FDA Rejects Ivonescimab, Gazyva Becomes the First Approved pMN Therapy, and a Nanobody Approval in Myasthenia Gravis

FDA issues a complete response letter for Summit Therapeutics’ PD-1/VEGF bispecific ivonescimab in EGFR-mutated non-small cell lung cancer, approves Roche’s obinutuzumab (Gazyva) for primary membranous nephropathy, and approves AstraZeneca’s nanobody C5 inhibitor gefurulimab (Klygefa) for generalized myasthenia gravis.

<iframe width="100%" height="95" src="https://embeds.audioboom.com/posts/8977581/embed?v=202301" style="background-color: transparent; display: block; padding: 0; width: 100%" frameborder="0" allowtransparency="allowtransparency" scrolling="no" title="Audioboom player" allow="autoplay" sandbox="allow-downloads allow-forms allow-popups allow-same-origin allow-scripts allow-storage-access-by-user-activation allow-top-navigation-by-user-activation"></iframe>

Welcome to The BioPharm Brief, your daily snapshot of developments shaping the biopharmaceutical industry. Today is all FDA decisions: a rejection that puts overall survival at center stage, a first-ever approval in a rare kidney disease, and a new format for complement inhibition.

First, FDA has rejected Summit Therapeutics’ ivonescimab with chemotherapy for EGFR-mutated non-small cell lung cancer previously treated with an EGFR inhibitor. It is the first PD-1×VEGF bispecific to seek US approval. In the phase 3 HARMONi trial, progression-free survival improved, but overall survival was 16.8 versus 14.0 months, which was not statistically significant. FDA concluded that a progression-free survival benefit without a significant overall survival benefit does not support a favorable benefit-risk profile. Summit says it will continue the drug’s development.

Next, FDA has approved Roche’s Gazyva for inducing remission of proteinuria in adults with primary membranous nephropathy who are at risk of disease progression. Roche calls it the first FDA-approved therapy for the disease. In the phase 3 MAJESTY trial, complete remission at two years was 36.1% with Gazyva versus 5.7% with tacrolimus. It is the antibody’s third FDA approval in immune-mediated kidney disease.

And finally, FDA has approved AstraZeneca’s Klygefa, or gefurulimab, for adults with anti-AChR antibody-positive generalized myasthenia gravis. It is a nanobody that inhibits complement C5 and also binds serum albumin, which extends its half-life. Patients give it to themselves once a week with a subcutaneous autoinjector. In the phase 3 PREVAIL trial, improvement versus placebo was seen as early as week 1.

That’s today’s BioPharm Brief. For analysis and expert insights, please visit BioPharmInternational.com.

Key takeaways

  • Survival bar: The ivonescimab rejection shows FDA requiring an overall survival benefit, not just progression-free survival, in this lung cancer setting.
  • First in class for the indication: Gazyva gives patients with primary membranous nephropathy their first approved therapy.
  • New formats: Klygefa brings nanobody-based C5 inhibition to patients as an at-home, once-weekly injection.

Related to this article

The BioPharm Brief: FDA’s Fast-Track Pilot Reportedly Stalls, a Long-Acting Bispecific for Atopic Dermatitis, and a Twice-Yearly Obesity Approach
FDA has reportedly shelved its Commissioner’s National Priority Voucher pilot and paused publishing complete response letters, Zai Lab’s IL-13/IL-31Rα bispecific ZL-1503 shows a 40- to 50-day half-life that points to dosing every 12 weeks, and Wave Life Sciences reports 1-year INLIGHT data for its INHBE-silencing siRNA WVE-007 in obesity.
The BioPharm Brief: An AI-Designed Multibody ADC Enters the Clinic, Blackstone Backs Pfizer’s Monthly GLP-1, and enGene Readies a Bladder Cancer BLA
FDA clears the IND for Biolojic Design’s BD200, an AI-designed Trop2/Nectin-4 multibody ADC; Blackstone Life Sciences agrees to provide Pfizer up to $1.5 billion to develop its monthly GLP-1 receptor agonist berobenatide; and enGene Therapeutics plans a year-end BLA for detalimogene voraplasmid in BCG-unresponsive non-muscle invasive bladder cancer.
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
FDA grants RMAT and Fast Track designations to AbelZeta’s CD20/CD19 bispecific CAR-T prizlon-cel in relapsed or refractory large B-cell lymphoma, Larimar Therapeutics completes a BLA seeking accelerated approval of nomlabofusp for Friedreich’s ataxia, and Merck’s GLP-1/glucagon receptor agonist efinopegdutide meets its primary endpoint in a phase 2b MASH trial.
The BioPharm Brief: argenx Bets on Peptides, a Two-Bispecific Regimen in Prostate Cancer, and a New Take on T-Cell Engagers
argenx agrees to acquire macrocyclic peptide developer Unnatural Products for up to about $1.15 billion, Johnson & Johnson’s pasritamig and JNJ-9401 bispecific regimen achieves a 73% PSA response in phase 1 in metastatic castration-resistant prostate cancer, and Janux Therapeutics’ TRBV6-targeted T-cell engager JANX011 shows deep B-cell depletion in healthy volunteers.
The BioPharm Brief: A Bispecific Approval in Head and Neck Cancer, TCR Bispecifics Head to the Clinic, and a New Antibody Target in Essential Thrombocythemia
FDA grants accelerated approval to Johnson & Johnson’s subcutaneous EGFR/MET bispecific Rybrevant Faspro for previously treated head and neck squamous cell carcinoma, T-Therapeutics raises a $133 million Series B to take TCR-CD3 bispecifics into clinical trials, and Alethio Therapeutics raises a $90 million Series A to advance its first-in-class G6B antibody for essential thrombocythemia.